NCT04796818 An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
| NCT ID | NCT04796818 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Metastatic Colorectal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2020-08-12 |
| Primary Completion | 2027-02-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2020-08-12 with a primary completion date of 2027-02-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial evaluates the treatment response of colorectal cancer that has spread to the liver (liver metastases) using intravoxel incoherent motion diffusion weighted imaging (IVIM DWI). IVIM DWI is new kind of imaging scan that may help measure changes in disease before and after chemotherapy in patients with colorectal liver metastases.
Eligibility Criteria
Inclusion Criteria: * Patients with treatment-naive resectable CLM, who will start chemotherapy with oxaliplatin with fluorouracil (5-FU)/leucovorin (FOLFOX), irinotecan with 5-FU/leucovorin (FOLFIRI), or a combination, such as fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), with or without a biologic agent * Patients with at least 1 colorectal liver metastasis measuring at least 1 cm * Patients with anticipated follow-up before and after surgery at MD Anderson Exclusion Criteria: * Patients who have already received preoperative chemotherapy for the CLM or will undergo radiation therapy, ablative therapies, or other non-surgical therapies directed at the liver * Patients allergic to gadolinium * Patients with pacemakers * Greater than 400 pounds in weight
Contact & Investigator
Priya R Bhosale
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT04796818 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Colorectal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04796818 currently recruiting?
Yes, NCT04796818 is actively recruiting participants. Contact the research team at priya.bhosale@mdanderson.org for enrollment information.
Where is the NCT04796818 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT04796818 clinical trial?
NCT04796818 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Priya R Bhosale at M.D. Anderson Cancer Center. The trial plans to enroll 70 participants.